Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2521-2540 of 3,900 trials

Actinic Keratosis: 5% Potassium Hydroxide Solution

We are studying whether a 5% potassium hydroxide solution is more effective than a placebo for treating mild to moderate actinic keratosis. The trial also looks at the safety of this treatment.

Actinic Keratosis3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

Headache Relief: Sphenopalatine Block for Subarachnoid Hemorrhage

We are studying whether a nerve block can help reduce headaches and the need for pain medication in patients with non-traumatic subarachnoid hemorrhage. This trial also looks at patient satisfaction and potential complications.

Subarachnoid Hemorrhage>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineNeurologyOtolaryngology

Pulmonary Hypertension: TX000045 Treatment Study

We are testing a new medication, TX000045, for patients with pulmonary hypertension due to heart failure. The goal is to see if it improves heart function and is safe for use.

Pulmonary Hypertension3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Oxygen Supply After Non-Cardiac Surgery: AIOLOS Trial

We are studying whether providing extra oxygen helps patients maintain better oxygen levels and improves recovery after non-cardiac surgery. This trial compares supplemental oxygen to standard care in the first days post-surgery.

Postoperative Complications Risk after General SurgeryPostoperative Complications Risk after Urology Surgery1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePulmonology

Mixed Dyslipidaemia: Rosuvastatin and Fenofibrate Study

We are comparing two medication combinations to see which one better lowers bad cholesterol in patients with mixed dyslipidaemia at high risk for heart disease. This study will help us understand their effectiveness and safety.

Dyslipidemia3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyEndocrinology

Pancreatic Cancer: Gemcitabine vs. Reduced-Dose Chemotherapy

We are studying whether standard-dose gemcitabine or a reduced-dose combination chemotherapy is more effective for fragile patients with non-resectable pancreatic cancer. This research aims to find the best treatment for those who cannot tolerate full-dose chemotherapy.

Pancreatic Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Primary Sclerosing Cholangitis: Norucholic Acid Tablets

We are studying the safety and tolerability of norucholic acid tablets for people with primary sclerosing cholangitis. We also want to see if it effectively helps manage their condition.

Primary Sclerosing Cholangitis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyHepatology

Borderline Personality Disorder and ADHD: BI 3031185 Study

We are testing how well BI 3031185 is tolerated by individuals with borderline personality disorder or ADHD. This study aims to gather information on its safety and side effects.

Borderline Personality DisorderAttention Deficit Hyperactivity Disorder6-12 monthsSafety phase (I)Psychiatry

FAPI PET Imaging for Pleural Mesothelioma

We are studying how effective FAPI PET scans are for diagnosing and staging pleural mesothelioma. This research may help improve treatment decisions and monitoring for patients with this condition.

Pleural Mesothelioma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyOtolaryngology

Vaginal Atrophy: New Estriol Vaginal Ring

We are testing a new vaginal ring that releases estriol to see if it improves vaginal health in postmenopausal women. The study will measure changes in vaginal tissue and pH after treatment.

Vulvovaginal Atrophy≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesEndocrinologyGynecology and Obstetrics

Acute Spinal Cord Injury: NG004 Treatment

We are testing a new antibody treatment for patients with acute spinal cord injuries to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Cervical Spinal Cord InjurySafety phase (I)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Cancer Treatment: ABP 234 vs. Keytruda

We are comparing a new treatment called ABP 234 with Keytruda for patients with cancer. This study aims to see which option may be more effective in managing the disease.

Advanced Non-Squamous Non-Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology

Ulcerative Pyoderma Gangrenosum: Spesolimab Study

We are testing whether spesolimab can help adults with ulcerative pyoderma gangrenosum heal their skin ulcers better than a placebo. This study aims to evaluate its safety and effectiveness.

Pyoderma GangrenosumConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementDermatology

Propofol Injection Pain Study

We are investigating whether propofol causes more pain than a placebo in healthy adults. This study aims to better understand pain levels during and after the injection.

Pain Relief1-2 yearsEfficacy phase (II)Standard MedicinesInternal MedicineOtolaryngologyPsychiatry

Cystectomy: Targeted Antibiotic Prophylaxis Study

We are testing whether a personalized antibiotic treatment can help reduce hospital readmissions due to infections after bladder surgery. This study compares it to the standard antibiotic approach used during stent removal.

Bacterial Infection3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesUrology

Rheumatoid Arthritis: Adalimumab Tapering Study

We are investigating the lowest effective dose of adalimumab for patients with rheumatoid arthritis in remission. The study also looks at how well patients tolerate the treatment and the development of antibodies.

Rheumatoid Arthritis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineRheumatology

Inhaled Levosimendan: Understanding How It Works

We are exploring how the body processes inhaled levosimendan in this early study. This research may help improve treatments for heart conditions.

Heart Failure>2 yearsSafety phase (I)CardiologyInternal Medicine

Trabectedin for HEY1-NOCA2 Positive Mesenchymal Chondrosarcoma

We are studying the effects of trabectedin in adults and young adults with advanced mesenchymal chondrosarcoma who have already received other treatments. The trial aims to assess how well this medication works in reducing tumors and improving patient outcomes.

Mesenchymal Chondrosarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Preventing Chemotherapy-Induced Nausea in Children: IV NEPA Study

We are studying a new intravenous treatment for children with cancer to see if it can effectively prevent nausea and vomiting during chemotherapy. This trial compares IV NEPA with standard treatments to ensure safety and effectiveness.

Chemotherapy-Induced Nausea and Vomiting3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncologyPediatrics

Spinocerebellar Ataxia and Huntington’s Disease: VO659 Treatment

We are investigating the safety of a new treatment given through the spine for people with spinocerebellar ataxia types 1 and 3, and Huntington’s disease. This study aims to understand how the body processes the medication.

Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology